Targeting NASH
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
NAFLD: a multisystem disease.
Byrne CD, Targher G. J Hepatol. 2015;62(suppl 1):S47-S64.
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL, et al. Hepatology. 2017 Aug 17. [Epub ahead of print].
Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Hannah WN Jr, Harrison SA. Hepatology. 2016;64(6):2234-2243.
Elevated serum ferritin is an independent predictor of histologic severity and advanced fibrosis among patients with nonalcoholic fatty liver disease.
Kowdley KV, et al. Hepatology. 2012;55(1):77-85.
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial.
Loomba R, et al. Hepatology. 2017 Sep 11. [Epub ahead of print].
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B, et al. Hepatol Int. 2016;10(4):632-639.
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA, et al. Lancet. 2015;385(9972):956-965.
Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.
Ratziu V, et al. Gastroenterology. 2016;150(5):1147-1159.
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
Ratziu V, et a. Hepatology. 2010;51(2):445-453.
Management of NAFLD: a stage-based approach.
Rinella ME, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2016;13(4):196-205.
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.
Targher G, et al. Diabetes. 2005;54(12):3541-3546.
Extrahepatic manifestations of nonalcoholic fatty liver disease.
VanWagner LB, Rinella ME. Curr Hepatol Rep 2016;15(2):75- 85.
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.
Wong RJ, et al. Gastroenterology. 2015;148(3):547-555.
Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes.
Younossi ZM, et al. Hepatology. 2016;64(1):73-84.
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.
Younossi ZM, et al. Hepatology. 2011;53(6):1874-1882.
Clinical Practice Guidelines
The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.
Chalasani N, et al. Hepatology. 2017 July 17. [Epub ahead of print]
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). J Hepatol. 2016;64(6):1388-1402.
Clinical Resources
Histological Scoring System for Nonalcoholic Fatty Liver Disease.
Transplant Pathology Internet Services, 2009.
MELD Score (Model for End-Stage Liver Disease) (12 and older).
MD+CALC online calculator, 2016.
NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score.
MD+CALC online calculator, 2016.
Patient Resources
American College of Gastroenterology (ACG) Patient Education and Resource Center.
The ACG website. provides a basic overview of NAFLD and includes patient-centered podcasts.
American Liver Foundation.
The American Liver Foundation website offers broad-based information and links to additional educational resources and support services for patients living with liver disease.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Health Information Center.
The NIDDK website for NAFLD and NASH provides comprehensive patient-centered information and resources, including an overview of clinical-trial participation.
Targeting NASH
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
| Faculty: | Zobair M. Younossi, MD, MPH, FAASLD (Chair); Vlad Ratziu, MD, PhD; Mary E. Rinella, MD |
| Release: | 01/24/2018 |
| Expiration: | 01/24/2019 |
